38 ANALYTICAL AND LABORATORY EQUIPMENT
Size doesn’t matter I
Aubree Hoover reveals why labs large or small can benefit from the latest in LIMS.
t turns out that rare diseases aren’t so rare. Because of an estimated 5,000-8,000 rare diseases, 1 in 17 people are affected. As our lifespans increase, cancer becomes less of a rarity as well.
To combat these inevitabilities, Genomics England, a company owned and funded by the UK Department of Health, recently announced a monumental project to sequence 100,000 genomes of people with cancer and rare diseases.
Genomics England has been forthcoming about anticipated challenges: sequencing that many genomes in the timeline specified, security of patient data, and translation of findings to the public. Te world will be watching as it navigates these challenges and undertakes this first-of-its kind project.
Not all projects are this massive in profile or size. Groundbreaking science –that helps diagnose and treat rare disease and cancer – takes place
should scale to whatever their sample throughput. Next, they must protect their investments: resources are tight and labs need to stretch their staff, reagent and instrument resources as much as possible.
Finally, they need tools that work in research or clinical environments. Many labs will be adding clinical applications to their sequencing line-up. Tey need tools that protect patient data privacy and support sequencing in a clinical or translational environment.
Yet, unlike Genomics England, they often don’t have as many resources. Enter the new era of laboratory information management systems (LIMS). Many labs resist the notion of a LIMS as it conjures the rigid and clunky systems of yesteryear. Additionally, many labs think LIMS are appropriate only for projects of the same magnitude as Genomics England. Tis simply isn’t true.
LIMS have come a long way, and good ones can help labs of any size (regulated or not) address challenges. Out-of-the-box instrument integrations can help labs scale to new technologies and increased sample volumes.
Fig. 1. The regulatory features in Clarity LIMS help labs of any size diagnose and treat rare disease and cancer.
To sequence 100,000 human whole genomes by the end of 2017, Genomics England has assembled an impressive set of tools: Illumina HiSeq X Ten genome sequencers; Clarity LIMS for laboratory information management; NextCode for analysis; Aridhia for annotation; and likely others.
Aubree Hoover is with GenoLogics Life Sciences Software in the USA.
www.genologics.com
www.scientistlive.com
Tese tools will help the company rapidly scale to factory- level production; provide fast, accurate and private results to patients; and analyse and annotate the data.
in start-up, core, academic or smaller clinical labs every day.
Tese labs face similar challenges as the Genomics England project. Tey need flexibility; they have a unique collection of tools. When technology and science advance, their tools must adapt and help manage change.
Tey also need scalability – they may not need to scale to 100,000 whole genomes in five years, but they will likely add services or increase sample volume. Teir existing tools
Configurable workflows and application programming interfaces (APIs) can help labs customise to their environments. QC features help labs monitor instrument performance and reagent use. And regulatory features help labs operate in a clinical environment if necessary. So, whether Genomics England or a start-up in some small corner of the world, the science is equally important and a good LIMS can help.
For more information ✔ at
www.scientistlive.com/eurolab
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120